- Home
- NZF vs AGIO Comparison
NZF vs AGIO Comparison
Compare NZF & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NZF | AGIO |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | NZF | AGIO |
|---|---|---|
| Price | $12.75 | $27.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $32.13 |
| AVG Volume (30 Days) | 496.8K | ★ 2.4M |
| Earning Date | 01-01-0001 | 10-30-2025 |
| Dividend Yield | ★ 4.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $44,791,000.00 |
| Revenue This Year | N/A | $25.57 |
| Revenue Next Year | N/A | $153.24 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.26 |
| 52 Week Low | $9.82 | $22.24 |
| 52 Week High | $12.29 | $62.45 |
Technical Indicators
Market Signals| Indicator | NZF | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 60.87 | 34.58 |
| Support Level | $12.56 | $26.81 |
| Resistance Level | $12.73 | $29.46 |
| Average True Range (ATR) | 0.10 | 1.99 |
| MACD | 0.01 | -0.75 |
| Stochastic Oscillator | 84.00 | 21.72 |
Price Performance
Historical ComparisonAbout NZF Nuveen Municipal Credit Income Fund
Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.